The CEO behind Tylenol thought he'd found a way to work with the Trump administration. Then everything went off the rails.

Core Insights - The CEO of the company behind Tylenol attempted to collaborate with the Trump administration to navigate regulatory challenges but faced significant setbacks [1] Group 1: Company Strategy - The CEO believed that aligning with the Trump administration could provide a pathway to address industry concerns and enhance business operations [1] - Initial discussions indicated potential support from the administration for the company's initiatives [1] Group 2: Challenges Faced - The collaboration efforts quickly deteriorated due to unforeseen political dynamics and internal company issues [1] - The company encountered resistance from various stakeholders, complicating its ability to implement proposed strategies [1]